Wedbush increased their Q2 2025 earnings per share estimates for SpringWorks Therapeutics in a research report issued on Wednesday, February 12th. Wedbush analyst D. Nierengarten now expects that the ...

Stock analysts at HC Wainwright dropped their FY2024 earnings per share estimates for SpringWorks Therapeutics in a research note issued on Wednesday, February 12th. HC Wainwright analyst R. Burns now ...

Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments ...

SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known ...

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability ...

TD Cowen raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $66 from $63 and keeps a Buy rating on the shares. The firm says ...

Daniel Pichl, the Chief People Officer of $SWTX, sold 13,750 shares of the company on 02-10-2025 for an estimated $728,997. We received data on the trade from a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptive Biotechnologies (ADPT – Research ...